drugset / Trial / NCT06016088
A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection.
Timeline
- Start
- 2024-04-01
- Primary completion
- 2026-04-15
- Completion
- 2026-06-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CaEDTA | Unknown | — | Inhaled |
| Subject | Tobramycin | Small molecule | 300 mg | Inhaled |